Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 1.00 |
| ▸ | HPGD | P15428 | 4/20 | 1.00 |
| ▸ | HTT | P42858 | 4/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.98 |
| ▸ | GAA | P10253 | 3/20 | 0.78 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.78 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.78 |
| ▸ | EEF2K | O00418 | 11/20 | 0.68 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.68 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13941637 | 0.98 | ALDH1A1 (0.96) | ALDH1A1HPGDHTTTDP1LMNA | |
| SCHEMBL4106730 | 0.85 | ALDH1A1 (0.74) | ALDH1A1HPGDHTTTDP1LMNA | |
| SCHEMBL4105366 | 0.85 | ALDH1A1 (0.74) | ALDH1A1HPGDHTTTDP1LMNA | |
| SCHEMBL13392917 | 0.85 | ALDH1A1 (0.81) | ALDH1A1HPGDHTTTDP1LMNA | |
| SCHEMBL5958465 | 0.85 | ALDH1A1 (0.74) | ALDH1A1HPGDHTTTDP1LMNA | |
| SCHEMBL3166845 | 0.84 | ALDH1A1 (0.79) | ALDH1A1HPGDHTTTDP1LMNA | |
| SCHEMBL13392961 | 0.84 | ALDH1A1 (0.74) | ALDH1A1HPGDHTTTDP1LMNA | |
| SCHEMBL2853029 | 0.84 | ALDH1A1 (0.73) | ALDH1A1HPGDHTTTDP1LMNA | |
| Hydrochloric Acid SCHEMBL4104360 | 0.84 | ALDH1A1 (0.72) | ALDH1A1HPGDHTTTDP1LMNA | |
| SCHEMBL4117723 | 0.84 | ALDH1A1 (0.72) | ALDH1A1HPGDHTTTDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3181568-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | Siga Technologies, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-3181568-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | Siga Technologies, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| EP-2400845-B1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECH INC (US) | 2017-02-22 | — | — | EP | disclosed |
| EP-2400845-B1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECH INC (US) | 2017-02-22 | — | — | EP | disclosed |
| US-20160152635-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-9301949-B2 | Thienopyridine derivatives for the treatment and prevention of dengue virus infections | SIGA TECHNOLOGIES, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9301949-B2 | Thienopyridine derivatives for the treatment and prevention of dengue virus infections | SIGA TECHNOLOGIES, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-8058285-B2 | Phosphodiesterase-4 (PDE-4) inhibitors; for treating bronchial asthma, COPD, rheumatoid arthritis (RA), osteoarthritis, cystic fibrosis, Guillain-Barresyndrome, Crohn's disease, ulcerative colitis, psoriasis, atopic dermatitis, allergic eczemas | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2011-11-15 | — | — | US | disclosed |
| WO-2010099166-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100190807-A1 | CDKI Pathway inhibitors and uses thereof to regulate expression to TAU protein | SENEX BIOTECHNOLOGY, INC. | 2010-07-29 | — | — | US | disclosed |
| EP-1773840-B1 | SUBSTITUTED PYRIDO[3',2':4,5]THIENO[3,2-D]PYRIMIDINES AND PYRIDO[3',2':4,5]FURO[3,2-D]-PYRIMIDINES FOR USE AS INHIBITORS OF PDA-4 AND/OR TNF-ALPHA RELEASE | MEDICINES CO LEIPZIG GMBH (DE) | 2010-01-20 | — | — | EP | disclosed |
| US-20090281129-A1 | CDKI PATHWAY INHIBITORS AND USES THEREOF | SENEX BIOTECHNOLOGY, INC. | 2009-11-12 | — | — | US | disclosed |
| US-20080160028-A1 | SUBSTITUTED PYRIDO [3', 2': 4, 5] THIENO [3, 2-D] PYRIMIDINES AND PYRIDO [3', 2': 4, 5] FURO [3, 2-D] PYRIMIDINES USED AS INHIBITORS OF THE PDE-4 AND/OR THE RELEASE OF TNF-ALPHA | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2008-07-03 | — | — | US | disclosed |
| US-20080160028-A1 | SUBSTITUTED PYRIDO [3', 2': 4, 5] THIENO [3, 2-D] PYRIMIDINES AND PYRIDO [3', 2': 4, 5] FURO [3, 2-D] PYRIMIDINES USED AS INHIBITORS OF THE PDE-4 AND/OR THE RELEASE OF TNF-ALPHA | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2008-07-03 | — | — | US | disclosed |
| US-20080160028-A1 | SUBSTITUTED PYRIDO [3', 2': 4, 5] THIENO [3, 2-D] PYRIMIDINES AND PYRIDO [3', 2': 4, 5] FURO [3, 2-D] PYRIMIDINES USED AS INHIBITORS OF THE PDE-4 AND/OR THE RELEASE OF TNF-ALPHA | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2008-07-03 | — | — | US | disclosed |
| US-20080033000-A1 | Identification of CDKI pathway inhibitors | SENEX BIOTECHNOLOGY, INC. | 2008-02-07 | — | — | US | disclosed |
| WO-2006010567-A1 | SUBSTITUTED PYRIDO[3', 2': 4, 5]THIENO[3,2-D]PYRIMIDINES AND PYRIDO[3', 2': 4, 5]FURO[3, 2, D]PYRIMIDINES USED AS INHIBITORS OF THE PDE-4 AND/OR THE RELEASE OF TNF$G(A) | CURACYTE DISCOVERY GMBH (DE) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080160028-A1 | SUBSTITUTED PYRIDO [3', 2': 4, 5] THIENO [3, 2-D] PYRIMIDINES AND PYRIDO [3', 2': 4, 5] FURO [3, 2-D] PYRIMIDINES USED AS INHIBITORS OF THE PDE-4 AND/OR THE RELEASE OF TNF-ALPHA | PDE4A, PDE3B, PDE4B | ALDH1A1 367/4885HPGD 149/4885HTT 4863/4885 |
| US-20100190807-A1 | CDKI Pathway inhibitors and uses thereof to regulate expression to TAU protein | MAPT, CDK5, CDKN1A | ALDH1A1 3956/4885HPGD 2336/4885HTT 292/4885 |
| US-20090281129-A1 | CDKI PATHWAY INHIBITORS AND USES THEREOF | CDKN1A, CDK6, CCNI | ALDH1A1 3833/4885HPGD 1183/4885HTT 930/4885 |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | TTPA, TPMT, SLC19A2 | ALDH1A1 1400/4885HPGD 205/4885HTT 2588/4885 |
| US-20160152635-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | TTPA, TPMT, SLC19A2 | ALDH1A1 1271/4885HPGD 188/4885HTT 2608/4885 |
| US-20080033000-A1 | Identification of CDKI pathway inhibitors | CDKN1A, CDK6, CDK2 | ALDH1A1 3133/4885HPGD 1074/4885HTT 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.